INTRODUCTION
The BRCA1 gene encodes multiple protein products, the most extensively studied of which is a large, multiply phosphorylated RING and BRCT motif-containing nuclear protein, p220. p220 is an E3 ubiquitin ligase, interacts with numerous protein partners, and plays a pivotal role in multiple aspects of the processes that maintain genomic integrity. In keeping with this finding, key elements of the gene have been conserved throughout plant and metazoan evolution, suggesting its participation in one or more fundamental cellular processes.
Based upon findings obtained in both cultured mammalian cells and a limited number of BRCA1 À/À breast and ovarian cancers, we proposed the existence of a significant relationship between the operations of p220 and the maintenance of elements of the heterochromatic superstructure of the inactive X chromosome (Xi) (Ganesan et al., 2002) . In particular, our results suggested a role for BRCA1 in maintaining the concentration of the large noncoding RNA XIST on Xi. The evidence published in Ganesan et al. (2002) included low-level but significant overlap of BRCA1 immunostaining with that of macrohistone H2A as well as with FISH staining of XIST RNA on Xi, the absence of XIST decoration of an X chromosome in a BRCA1 mutant human tumor cell line and its reappearance after restoring wild-type (WT) p220 protein synthesis, marked reduction of XIST/Xi decoration following RNAimediated p220 depletion, and the absence of an inactive X chromosome in all members of a small collection of BRCA1 mutant tumors. The mechanism linking XIST/Xi decoration to BRCA1 function was not investigated beyond the finding that induction of BRCA1 synthesis in a BRCA1 mutant tumor cell line was accompanied by the appearance of XIST/Xi decoration but no increase in XIST abundance. By default, this suggested that BRCA1 contributes to steps that support the concentration of XIST on Xi rather than playing a prime role in its synthesis or degradation. That notwithstanding, we indicated that one could not rule out from our results a more general role for BRCA1 in regulating XIST synthesis. Xiao et al. (2007) , in this issue, question the validity of these conclusions, and we have taken their concerns to heart. As a first step, we have successfully reproduced the findings of Ganesan et al. (2002) . Second, a new body of work has been completed, and the results of these studies are presented here. The new data reinforce and extend our original conclusions, which are also bolstered by the publication of complementary findings by others (Chadwick and Lane, 2005; Diaz-Perez et al., 2006; Ouyang et al., 2005) . Specifically, we have confirmed the conclusion of Ganesan et al. that RNAi of BRCA1 decreases XIST concentration on Xi by extending the RNAi results from human to mouse cells using different target sequences. In addition, we have confirmed the relationship of BRCA1 to XIST concentration on Xi by demonstrating that depleting BRCA1 by Cre-mediated excision also decreases XIST concentration on Xi. Lastly, we demonstrate that mouse tumor lines derived from true Brca1 null mammary tumors do not show XIST RNA concentration on Xi despite the presence of two X chromosomes.
RESULTS
A major claim of Xiao et al. (2007) (this issue of Cell) relates to whether BRCA1 colocalizes with XIST on Xi. Xiao et al. state that they lack consistent evidence to support our finding that a small minority of asynchronous cultured cells reveal colocalization of BRCA1 immunostaining and XIST FISH signals on the inactive X chromosome (Xi) (Ganesan et al., 2002) . Second, Xiao et al. also question whether RNAi-mediated BRCA1 depletion affects XIST. They report that our data linking BRCA1 knockdown to decreased XIST signal on Xi are not reproducible. Finally, they question whether Xi is absent in Brca1 mutant breast cancers. Contrary to Ganesan et al. (2002) , Xiao et al. report that loss of BRCA1 function is not accompanied by concomitant loss of XIST/Xi decoration in Brca1 À/À murine tumors. We will address each of these points below.
Detection of BRCA1 at Xi
In their analysis, Xiao et al. (2007) have interpreted meaningful colocalization of BRCA1 and XIST to occur only when BRCA1 completely coats the territory of Xi with perfect coincidence of both images. This is a narrower definition of colocalization than we used. To be scored positive for colocalization, we required, at a minimum, a significant degree of apposition (i.e., partial fluorescent signal overlap) between BRCA1 and XIST or macrohistone H2A (mH2A), and this was repeatedly observed in a small minority of asynchronous cells in multiple cell lines. Our work has been reproduced in part and extended by Chadwick and Lane (2005) , who demonstrated significant costaining by both BRCA1 antibody and either mH2A or BUdR antibody of Xi in multiple human cell strains in late S phase. Multiple BRCA1 antibodies were used. These findings fit with our observation that ''costaining was largely apparent in mid/late S phase cells.'' Very recently, significant S phase-associated apposition of BRCA1 and Xi was also reported independently by others as part of a more general interaction of BRCA1 and replicating heterochromatin-dense chromosomal structures .
Despite the call by Xiao et al. (2007) for a perfect fit of XIST and BRCA1 images as the only indicator of biological significance, it has been shown that certain Xi territory markers, such as H3K27 methylation, only partly overlap other Xi markers (Chadwick and Willard, 2004; Figure S3 in Xiao et al., 2007) because Xi heterochromatic territory is heterogeneous. Two distinct Xi regions, one marked by XIST, MH2A, and H3mK27 and the other by H3mK9 and HP1g (a BRCA1 partner protein; S.G. and D.M.L., unpublished data), have been detected (Chadwick and Willard, 2004) . BRCA1 has been said to associate with both of these Xi territories, although likely at different times during Xi replication (Chadwick and Lane, 2005) . Thus, perfect BRCA1/Xi marker costaining in asynchronous cells should be very uncommon or absent, as confirmed by Xiao et al., while partial overlap of XIST or other Xi-associated elements and BRCA1 in a minority of cells in an asynchronous culture would be an expected result. Notably, subsequent to our previous publication (Ganesan et al., 2002) , other investigators published evidence of robust BRCA1/Xi costaining in mouse cells (Diaz-Perez et al., 2006; Ouyang et al., 2005) . We, too, continue to detect such an association in a minority of asynchronous cells (see Figure S1 in the Supplemental Data available with this article online).
Given these findings, we would argue that our original evidence of BRCA1 immunostaining on a significant fraction of Xi territory in a small subset of unsynchronized cells has been reproduced and extended by newer results of other laboratories. The biochemical significance of these findings requires further work. Xiao et al. (2007) report that attempts to knock down BRCA1 expression with RNAi failed to change the intensity of XIST/Xi signals. Ganesan et al. (2002) reported that RNAi-mediated depletion of BRCA1 in primary human cells led to suppression of XIST/Xi staining in many cells. Here we discuss the possible reasons for the difference in results with RNAi-mediated knockdown and present new data confirming our original RNAi data in another species.
Effects of BRCA1 RNAi-Mediated Depletion on XIST Concentration on Xi
With respect to the RNAi-mediated knockdown, we, too, have observed in some experiments using BRCA1-specific RNAi (even using the pooled, commercial BRCA1 RNAi reagent that Xiao et al. [2007] used) that S phase BRCA1 nuclear dots largely disappear, but nothing happens to XIST. When BRCA1 protein levels were analyzed by western blots in these experiments, there was, typically, limited BRCA1 protein depletion (e.g., 50%-70%). However, when knockdowns approached R90% or more, as seen in mouse X3 cells in Figures 1A and 1B , widespread reduction in XIST/Xi staining was observed. This may well be an indication that residual, low-level BRCA1 function is sufficient to support robust XIST/Xi staining. In this regard, BRCA1/BARD1 heterodimers are potent enzymes, and for a BRCA1 function (mitotic spindle development) for which its enzyme function is required, >95% BRCA1 protein depletion was needed to elicit an abnormal phenotype (Joukov et al., 2006) . Figures 1A and 1B support our earlier findings and weaken the case for off-target/nonspecific RNAi effects since this RNAi reagent targets a different sequence in a different species from those targeted in our prior results (Ganesan et al., 2002) . There is also a technical matter worth considering. Ganesan et al. and the experiment depicted in Figures 1A and 1B utilized an XIST RNA-FISH probe containing digoxigenin-modified nucleotides, visualized with a fluorescently labeled anti-digoxigenin antibody. We have subsequently observed that probes made with nucleotides directly coupled to fluorescent moieties visualize lower levels of XIST than digoxigenin-labeled ones. These types of probes were employed in the conditional mouse embryonic fibroblast (MEF) experiments below and by Xiao et al. Although the use of these more powerful probes tends to decrease the percentage of cells with no visible XIST in RNAi experiments compared with digoxigenin probes, clear reductions in XIST intensity are still present. Specifically, these more sensitive probes did not mask the overall finding that highly efficient RNAi of BRCA1 decreases the concentration of XIST on Xi in our hands.
Studies of Brca1 and Brca2 Conditional MEFs
As an independent and more stringent test of the hypothesis that loss of BRCA1 affects XIST/Xi decoration, BRCA1 depletion was achieved and the state of XIST assessed in conditional Brca1 knockout cells. Specifically, MEFs in which either one or two Brca1 or Brca2 conditional (floxed) alleles were present were analyzed. In the conditional Brca1 allele, exons 5-13 are flanked by loxP sites, and in the conditional Brca2 allele, exon 11 is flanked by loxP sites (Clark-Knowles et al., 2007; Jonkers et al., 2001 ). When exposed to Cre, these conditional Brca1 and Brca2 alleles develop into null alleles. When Brca1 flox/flox MEFs were exposed to a self-excising, Cre-encoding retrovirus (Silver and Livingston, 2001) , levels of BRCA1 p220 fell dramatically, without an effect on the BRCA2 protein ( Figure 2A ). The opposite was true in infected Brca2 flox/flox MEFs. Furthermore, in independent experiments, Cre transduction resulted in efficient genomic deletion as judged by Southern blotting ( Figure 2B ) and elimination of BRCA1 protein immunostaining in S phase cells X3 cells were transfected with a Brca1-specific siRNA (number 4109, directed against a sequence in exon 12 of murine Brca1, an exon common to all known splicing variants of Brca1) or control siRNA. After a 24 hr incubation at 37 C, cells were split 1:3, and 48 hr later, they were fixed and subjected to BRCA1 immunostaining with a mouse monoclonal antibody to murine BRCA1 p220 followed by XIST RNA-FISH. (A) BRCA1 and XIST RNA-FISH images of control-and 4109-transfected cells.
(B) In a separate experiment, an IP/western blot for BRCA1 was performed on X3 cells either mock transfected or transfected with luciferase-specific (control) or Brca1-specific siRNA. J103 is an affinity-purified rabbit antibody raised against a murine BRCA1 peptide sequence present in exon 8. GH118 is a murine monoclonal antibody directed against BRCA1. ( Figure S3A ). The presence of a Rosa26 locus-embedded lox-stop-lox-lacZ allele (R26R) (Soriano, 1999) in some of these MEF strains permitted assessment of Cre activity. Efficient Cre-mediated deletion was reflected by lacZdependent X-gal staining in >90% of cells in the Cre-infected MEFs containing the R26R allele (data not shown).
A different manifestation of the absence of BRCA1 or BRCA2 function was also observed in Cre-treated conditional cells ( Figure 2C and Figure S3B) Five days after Cre virus or mock infection, XIST RNA-FISH was performed on conditional Brca1, conditional Brca2, and control MEFs, and an investigator blinded to the identity of the cultures being analyzed obtained multiple photomicrographs from each. The photomicrographs were scored for XIST/Xi staining intensity by four blinded analysts ( Figure 3 and Figure S2 ). Representative pictorial examples of such fields and a semiquantitative analysis of the results obtained by the blinded analysts revealed that only cells that had lost both Brca1 alleles experienced an overt, statistically significant (p < 0.0001) reduction in focal XIST/Xi staining by comparison with controls analyzed in parallel ( Figure 3C ). Similar results were obtained using MEFs of the same genotypes derived from separate embryos in an independent experiment (data not shown). The reduction in XIST/Xi intensity in Brca1 null cells was not a result of a proliferation block/defect, because no such reduction was observed in Brca2 null cells, which experienced a proliferation effect similar to Brca1 null cells (Patel et al., 1998; Xu et al., 1999) . Indeed, FACS analyses of Brca1 À/À and Brca2 À/À MEFs generated by this approach revealed no major changes in the distribution of cell-cycle intervals from that of Cre-treated WT MEFs. This implies that the proliferation defect in the nullizygous cells was a result of a general slow-down in cell-cycle progression (D.P.S. and D.M.L., unpublished data).
Hence, acute homozygous Brca1, but not Brca2, loss of function in conditional MEFs resulted in a significant diminution in the intensity of XIST/Xi staining.
XIST/Xi in Breast Tumors Arising in Brca1 Germline Mutant Mice Xiao et al. (2007) report that cells of mammary tumors arising in mice engineered to produce a homozygous Brca1 mutation (D11/D11) in mammary tissue contain XIST/Xi foci. The authors argue that this result runs counter to our observations that human BRCA1 À/À tumors lack robust XIST and H3meK27/Xi foci (Ganesan et al., 2002) . Here we discuss possible reasons for the discrepancies in the results and report new data examining XIST staining and localization in cell lines derived from Brca1 null tumors generated in a conditional Brca1 knockout mouse model. In our view, the discrepancy between our original results and those of Xiao et al. (2007) may reflect the nature of the different Brca1 mutations in the two sets of experiments. Brca1 D11, the mouse Brca1 mutant allele studied by Xiao et al., is a hypomorph, not a null mutation (Brodie and Deng, 2001) . It results from a clean deletion of Brca1 exon 11 and, unlike null mutants, leaves intact a normal, naturally occurring alternatively spliced BRCA1 protein, D11. Brca1 À/À (null) mutant murine embryos die early in embryogenesis, even when bred onto a p53 mutant background (Ludwig et al., 1997) . In contrast, Brca1 D11/D11 ;p53 +/À mice are born and become viable adults (Xu et al., 1999 (Xu et al., , 2001 ). The females tend to develop mammary tumors. Moreover, the D11 protein retains certain WT p220-like properties both in mitotic cells (Huber et al., 2001 ) and in a minority of pachytene spermatocytes (Turner et al., 2004) . In addition, some organisms completely lack an exon 11-like unit; for example, the WT C. elegans BRCA1 ortholog lacks these sequences yet performs normal DNA damage-response functions (Boulton et al., 2004) . Finally, BRCA1 D11 protein retains an ability to localize in subnuclear foci indistinguishable from BRCA1 p220 (Huber et al., 2001 ). Since D11 retains certain WT BRCA1 functions, it is difficult with the available evidence to know whether D11 mammary tumors emerge via the same molecular and biological pathway (or pathways) as null BRCA1 À/À human tumors. In addition, mammary epithelial cell-associated p53 mutations alone can give rise to murine breast cancer (Lin et al., 2004) , raising the question of whether some of the D11 tumor cells analyzed in Xiao et al. are actually Brca1 WT, p53 mutant. We have found that cell lines derived from tumors arising in Brca1 conditional, p53 conditional mammary epithelia exposed to Cre are not infrequently p53 mutant but Brca1 WT. Xiao et al. offer no evidence that the tumor lines that they analyzed harbor Brca1 mutations. In fact, at least one of the cell lines analyzed in Xiao et al., W0069, appears to be Brca1 WT ( Figure S4 ). Hence, for the reasons noted here, the presence of a normal Xi in cells derived from murine D11 mammary tumors analyzed in Xiao et al. might not be remarkable. In this regard, the human L56Br-C1 cell line studied by Xiao et al. and found to contain XIST/Xi structures carries a translation-terminating BRCA1 mutation within exon 11 that should, in principle, leave the endogenous D11 mRNA intact (Johannsson et al., 2003) . If D11 protein positively influences XIST/Xi costaining, this line could have retained that function.
To determine the status of XIST localization in murine tumors carrying true null Brca1 alleles, we have employed a conditional Brca1 mouse model in which exons 5-13 are flanked by loxP sites (the same allele used in the Brca1
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floxed MEFs described above). The Jonkers laboratory has used these mice to generate Brca1 null mammary carcinomas using a cytokeratin 14 promoter-driven Cre transgene (K14cre; Jonkers et al., 2001) in the context of conditional p53. In a blind analysis performed in three separate laboratories, none of the cultures of six independently derived clonal cell lines from two Brca1 null tumors revealed focal XIST spots ( Figure 4A ). The absence of XIST spots was not a result of X monosomy, given the presence of at least two X chromosomes in cells of these tumor lines when analyzed by DNA-FISH ( Figure 4B ). The Brca1 null genotype of each line was confirmed by allele-specific PCR, and all six lines lacked BRCA1 nuclear foci when examined by immunofluorescence (data not shown). Cells derived from control mammary tumors in which only p53 was targeted showed both intact BRCA1 nuclear foci and robust focal XIST staining (Figure 4 and data not shown).
To explore the XIST status of additional BRCA1 mutant cell lines, we have recently performed XIST RNA-FISH on the five human BRCA1 mutant cell lines available in our laboratory, four of which were not known to be BRCA1 , was also tested. Only L56Br-C1 displayed focal XIST staining, whereas focal XIST could not be detected in the other four lines ( Figure S5 ). We agree with Xiao et al. (2007) that there are undoubtedly BRCA1 WT cell lines and tumors that lack focal XIST staining, most likely a result of Xi loss. However, among BRCA1 À/À carcinomas, loss of focal XIST staining was more common than in breast carcinomas-even high grade lesions-of other pathological subtypes (Richardson et al., 2006) .
The human tumor data in our original paper have been confirmed in a more recent analysis from our group (Richardson et al., 2006) . We report a lack of focal XIST and H3meK27 spots in all five new human BRCA1 À/À breast carcinoma samples examined. This paper also described a similar XIST/Xi loss phenotype in 14 out of 17 cases of sporadic basal-like breast cancer. Sporadic basal-like carcinomas are BRCA1 WT yet are a known BRCA1 À/À breast carcinoma phenocopy, sharing a similar gene expression pattern, a similar estrogen and progesterone receptor and cytokeratin expression phenotype, a lack of HER2 amplification, and p53 mutation status with BRCA1 À/À breast cancers (Richardson et al., 2006; Sorlie et al., 2003) . Thus, it is tempting to speculate that the sporadic basal-like breast cancers are defective in a pathway (or pathways) in which BRCA1 participates and may, therefore, share XIST loss with hereditary BRCA1 À/À breast cancers. This notwithstanding, given the relatively small number of tumors analyzed, there may well be some BRCA1 À/À human tumors with XIST/Xi structures. The nature of the relevant BRCA1 mutant genotypes in settings where XIST is absent compared to any where it is present would need to be considered. If, as suggested by Xiao et al. (2007) , low-level XIST synthesis from Xa occurs, this, too, could account for XIST foci in some tumor cells.
DISCUSSION
We believe that the data reported here help to explain the apparent discrepancies noted by Xiao et al. (2007) and reinforce the view that BRCA1 influences, directly or indirectly, XIST decoration of Xi in adult somatic cells. Xiao et al. present four lines of evidence in support of their view that BRCA1 does not influence XIST localization. First, they argue that BRCA1 does not ''coat'' the inactive X chromosome. However, in Ganesan et al. (2002) , no claim was made that BRCA1 perfectly coats Xi or provides the prime force that drives XIST/Xi coating, e.g., during embryogenesis; rather, in a small percentage of cells, a percentage that varied among the cell types examined, BRCA1 exhibited overlapping staining with XIST or with a marker of Xi, macrohistone H2A. suspect that the inability of Xiao et al. to restore strong, focal XIST staining may relate to differences in the X chromosomal content of subclones. Early passages of BRCA1-reconstituted HCC1937 were sent to another laboratory, and they reproduced our finding that, unlike either parental HCC1937 or vector-reconstituted HCC1937, the majority of BRCA1-reconstituted HCC1937 showed focal XIST staining, with the majority of these cells having two X chromosomes . While another BRCA1-reconstituted HCC1937 subclone showed no focal XIST, it contained only one X chromosome . Third, the RNAi experiments of Xiao et al. (2007) were interpreted by the authors to reveal no effect of BRCA1 RNAi on XIST staining. However in interpretation are based on the view that XIST coating of Xi is an ''all or nothing'' phenomenon. Our experiments and others that we are aware of suggest that XIST is in dynamic equilibrium with Xi and that the initiation and maintenance of XIST coating may be separable functions. Whatever the case, the conditional knockout of BRCA1 avoids the pitfalls of incomplete RNAi and demonstrates an effect of BRCA1 loss on XIST/Xi intensity. Xiao et al. (2007) analyzed murine tumors and cell lines derived from them that were all generated in a mouse model that deletes Brca1 exon 11. As described above, this is a hypomorphic mutation (Brodie and Deng, 2001) . Because this mutation preserves a naturally occurring BRCA1 isoform, D11, it is difficult to predict what the outcome of such a knockout would be on any particular BRCA1 function. Furthermore, as discussed above, the Brca1 D11/D11 genotypic status of the tumors presented in Xiao et al. is unclear since at least one of them examined by us appears to be Brca1 WT ( Figure S4 ). Xiao et al. also presented an analysis of RNA expression of genes along the X chromosome in both embryonic and mammary tissue from D11 homozygous mice compared with D11 heterozygous mice to show that BRCA1 loss does not influence Xi silencing. However, Ganesan et al. (2002) did not claim a global failure of Xi silencing or widespread reactivation of X-linked genes as a result of BRCA1 loss. What was observed was a low-level reactivation of a GFP reporter embedded in Xi following BRCA1 depletion and, in later work, upregulation of a small subset of X-encoded genes in five BRCA1 À/À breast carcinomas (Richardson et al., 2006) . Xiao et al. have also argued that our results demonstrating Xi loss in sporadic basal-like cancer (BLC), a BRCA1 WT tumor, invalidate the argument that Xi loss in BRCA1 À/À tumors is a BRCA1 mutation-associated event.
However, as discussed above, sporadic BLCs are wellknown phenocopies of BRCA1-deficient tumors (Turner et al., 2004; Lacroix and Leclercq, 2005) . Not unexpectedly, then, sporadic and BRCA1 mutant BLCs share another property-i.e., loss of a normal Xi, a feature that is rare in aggressive, nonbasaloid breast cancer cases (Richardson et al., 2006) . Moreover, the tumor cells of a majority of the BRCA1
and sporadic basal-like tumors that have been reported have undergone X isodisomy, with the active X being duplicated and Xi lost (Richardson et al., 2006) . On its face, this would seem to be at odds with the notion that BRCA1 abundance contributes to active XIST/Xi decoration. However, it is worth noting that BRCA1 is a multifunctional protein, one operation of which is to promote stable mitotic spindle pole and spindle formation (Joukov et al., 2006) . Another is to participate in centrosome operations (Parvin and Sankaran, 2006; Xu et al., 1999) . In the absence of sufficient BRCA1 p220, spindle formation is compromised, resulting in a variety of abnormal mitotic phenotypes. Moreover, aneuploidy is known to develop shortly after loss-of-function mutation of both copies of the BRCA1 gene (Shen et al., 1998) , and the genomes of BRCA1 À/À and sporadic basal-like tumors are overtly unstable (Chappuis et al., 2000) . This may help to explain why chromosomal abnormalities (including X isodisomy) are so prevalent in cells that have either lost BRCA1 function per se or encountered defects in pathways in which BRCA1 normally participates.
There being no a priori or independent evidence that BRCA1 operates as a dosage-compensation element, we speculate that it plays a different kind of role in the biology of Xi. BRCA1 is a genome integrity maintenance protein that contributes to DNA repair, checkpoint activation, mitotic spindle development, and possibly the centrosome cell cycle (Gudmundsdottir and Ashworth, 2006; Joukov et al., 2006; Parvin and Sankaran, 2006) . Thus, communication between BRCA1 and XIST/Xi might be a manifestation of a BRCA1 genome integrity maintenance function. In this regard, recent evidence from Marahrens and coworkers (Diaz-Perez et al., 2006) strongly suggests that engineered loss of the Xist gene is associated with subsequent X chromosomal damage. Moreover, a replicating Xi is reported to accumulate g-H2AX (Chadwick and Lane, 2005) , a signal that often reflects DNA damage-e.g., double-strand breaks associated with stalled replication forks. In this context, one wonders whether failure of XIST to concentrate on Xi in the absence of BRCA1 promotes damage to and subsequent loss of Xi and, if so, whether loss of Xi in that setting is compensated by the duplication of Xa. Finally, have shown that BRCA1 displays a significant association, especially during S phase, with certain heterochromatin-containing nuclear structures, Xi being but one of them. This set of findings raises the interesting possibility that communication between BRCA1 and Xi may well be a reflection of a larger role for BRCA1 in maintaining heterochromatin structure or function. Ten microliters of each 20 mM siRNA (Dharmacon) was diluted in 250 ml of Opti-MEM I medium (Invitrogen). Ten microliters of Lipofectamine 2000 was diluted in 250 ml of Opti-MEM I, incubated for 5 min at room temperature, and added to the diluted siRNA. After 20 min of incubation at room temperature, samples were added to the individual wells containing 2 ml DMEM + 10% FBS. After 24 hr of incubation at 37 C, cells were split 1:3, plated on glass coverslips in six-well plates, and analyzed 48 hr later.
Conditional Deletion of Brca1 and Brca2
MEFs were prepared from embryos containing alleles with loxP sites encompassing exons 5-13 of Brca1, labeled Brca1 flox (Clark-Knowles et al., 2007) ; embryos containing with loxP sites encompassing exon 11 of Brca2 (Jonkers et al., 2001) , labeled Brca2 flox ; embryos with corresponding germline deletions; or embryos containing WT Brca1 or Brca2 alleles. Early-passage MEFs were infected with a self-excising Cre retrovirus (Silver and Livingston, 2001 ) on two successive days or were handled identically, except that virus was not added. For XIST experiments, cells were split once after infection, and RNA-FISH for XIST was performed 5 days after the first infection. et al., unpublished data) were collected aseptically by blunt dissection. Tumors were mechanically dissociated by mincing and sorted through a 40 mm Falcon strainer to remove larger tumor cell aggregates. Cells were cultured in DMEM/F12-GlutaMAX (GIBCO) supplemented with 10% fetal bovine serum (Greiner Bio-One), 5 mg/ml insulin (Sigma), 5 ng/ml EGF (Invitrogen), and 5 ng/ml cholera toxin (Sigma) and incubated at 37 C under 5% CO 2 . Four days later, fibroblasts were removed by partial digestion with 13 trypsin-EDTA (GIBCO), and epithelial subpopulations were selected manually. Once regrown, clonal cell lines were derived from these subpopulations by limiting dilution, and the clones were genotyped as described (X.L. et al., unpublished data).
Derivation of Mouse Tumor Lines

Indirect Immunofluorescence
Mouse cells grown on glass coverslips were washed three times with PBS, fixed in 3% paraformaldehyde/2% sucrose solution for 10 min at room temperature, washed twice with PBS, and permeabilized with PBS/0.05% Triton X-100 for 5 min at room temperature. Cells were then incubated with primary anti-BRCA1 monoclonal antibody GH118 in 43 SSC, 1 mg/ml BSA, 0.5 mg/ml salmon sperm DNA, 10 U/ml RNasin for 1 hr at 37 C; washed twice for 5 min in PBS; and incubated with a FITC-conjugated goat anti-mouse secondary antibody (Jackson ImmunoResearch) for 1 hr at 37 C, followed by three PBS washes.
Coverslips were processed further for RNA-FISH or mounted on slides with DAPI-containing mounting medium (Vector Laboratories) and kept at 4 C until analysis. For immuno-RNA-FISH, cells were fixed again as above with paraformaldehyde/sucrose and processed for RNA-FISH.
RNA-FISH
Cells were washed three times in PBS, fixed in 3% paraformaldehyde/ 2% sucrose solution for 10 min at room temperature, washed twice in PBS, permeabilized with PBS/0.05% Triton X-100 for 5 min at room temperature, washed again three times in PBS, incubated in cold 70% ethanol for 2 hr at 4 C, incubated for 10 min in ice-cold 100% ethanol, and air dried. For the mouse X3 cell experiments, Xist probe was prepared by labeling with digoxigenin-11-dUTP (DIG-Nick Translation Mix, Roche Applied Science). One microgram of plasmid encoding mouse XIST and 4 ml DIG-Nick Translation Mix were resuspended in double-distilled water to a final volume of 20 ml and incubated for 2.5 hr at 15 C. The reaction was stopped by addition of 2.5 ml of 10% SDS and 5 ml of 0.5 M EDTA (pH 8.0) followed by incubation for 10 min at 90 C. After precipitation with 0.1 vol 3 M NaOAc, 2.5 vol 100% EtOH, and 2 ml salmon sperm DNA (10 mg/ml)/tRNA (10 mg/ ml) (Invitrogen), probe was washed with 70% EtOH, air dried, and resuspended in 80 ml double-distilled water. Five microliters of this digoxigenin-labeled Xist probe, 12 ml of human Cot-1 DNA (Invitrogen), and 2 ml salmon sperm DNA/tRNA were mixed and dried in a speed vacuum for 35 min. The pellet was resuspended in 10 ml of 100% formamide and denatured for 10 min at 95 C. After addition of 10 ml of 4:1 mix of RNA hybridization buffer (1 ml 7.5% BSA, 1 ml 203 SSC, 2 ml 50% dextran sulfate)/VRC (vanadyl ribonucleoside complex, Invitrogen), the mix was applied to the coverslip and hybridized overnight at 37 C. Coverslips were washed for 20 min in 50% formamide/23 SSC at 37 C, 20 min in 23 SSC at 37 C, and 20 min in 13 SSC at room temperature; incubated in anti-digoxigenin secondary antibody (1:200 in 43 SSC, 1% BSA) for 1 hr at 37 C; and washed in 43 SSC for 10 min at room temperature, 43 SSC/0.1% Triton X-100 for 10 min at room temperature, and 43 SSC for an additional 10 min at room temp. Coverslips were mounted on slides with DAPI-containing mounting medium (Vector Laboratories) and kept at 4 C until analysis.
For the experiments with conditional MEFs, 1 mg of a plasmid encoding mouse XIST was directly labeled per the manufacturer's instructions (Vysis). The probe was then ethanol precipitated, washed in 70% ethanol, and air dried. The probe was then resuspended in 225 ml RNA hybridization buffer (1 part 20 mg/ml BSA, 1 part 203 SSC, 2 parts 50% dextran sulfate) to make a probe stock. Four parts of probe stock were diluted in 1 part VRC and 5 parts 100% formamide, denatured at 80 C for 10 min, and hybridized overnight at 37 C. The slides were then washed and processed as above.
DNA-FISH
Murine cell lines were grown on glass coverslips, fixed in 3% buffered paraformaldehyde, and processed for DNA-FISH as described previously (Clemson et al., 1996; Lee and Jaenisch, 1997) . To prepare murine X chromosome-specific probes, murine X chromosome BACs (51A16 and 23H12) validated for FISH were used (Korenberg et al., 1999) . Digoxigenin-labeled probes were generated from these BAC templates using a DIG-Nick Translation Kit (Roche Applied Sciences). After hybridization with labeled probe, cells were then incubated with rhodamine-labeled anti-digoxigenin Fab fragments at a final concentration of 1 mg/ml (Roche Applied Sciences). After washing, coverslips were mounted on glass slides with Vectashield containing DAPI (Vector Labs). Staining was visualized on a Zeiss Axiophot fluorescence microscope, and images were captured with a CCD camera.
Southern and Western Blots
Southern blotting was performed with high-salt buffer as described (Ausubel et al., 1999) . Hybond-XL membrane and Ambion ULTRAhyb were used per the manufacturer's instructions. A probe consisting of exon 14 sequences from murine Brca1 was prepared by digesting the murine Brca1 cDNA with BglII and SacI, isolating the resulting 257 bp fragment, and labeling with 32 P using a Boehringer Mannheim Random Primed DNA Labeling Kit. A probe for murine Brca2 exon 14 was prepared by PCR using the forward primer 5 0 -GCTTCTGTCTAAAGGG CATC-3 0 and the reverse primer 5 0 -TCTTCCCTGTCTCCATCT-3 0 . Total genomic DNA was digested with EcoRV in the case of Brca1 and KpnI in the case of Brca2. Digested genomic DNA was electrophoresed on a 0.7% agarose gel. For immunoblots, cell extracts were prepared in NETN (150 mM NaCl, 1 mM EDTA, 20 mM Tris [pH 8.0], 0.5% NP40). Semidry western transfers were performed as described in Scully et al. (1997) . Signals were detected by ECL (Amersham). Murine BRCA1 was visualized with monoclonal antibody GH118 (Ganesan et al., 2002) and murine BRCA2 with a polyclonal affinity-purified anti-BRCA2 antibody (D.P.S. and D.M.L., unpublished data).
Chromosome Spreads
Brca1 conditional MEFs of the various genotypes were either infected or mock infected with a self-deleting Cre retrovirus. Seventy-two hours later, chromosomal spreads were prepared as described in Silver and Livingston (2001) .
Statistical Methods
Photomicrographs were made for each of the six categories of MEFs in Figure 3 . Experimenters blind to the genotype of the MEFs scored each as having XIST intensity 0, 1, 2, or 3 based on the training slides in Figure 3B . For each experimenter on each photomicrograph, the average XIST intensity score (over all cells in the photomicrograph) was calculated, and the averages from the Brca1 flox/del Cre were compared to the averages from the other types of MEF using a two-sided exact Wilcoxon rank-sum test.
Supplemental Data
Supplemental Data include five figures and can be found with this article online at http://www.cell.com/cgi/content/full/128/5/991/DC1/.
